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Abstract. Multimorbid patients taking polypharmacy represent a growing 
population at high risk for inappropriate prescribing. Various lists for identifying 
potentially inappropriate medication are spread across scientific journals and 
difficult to access. To address this ongoing need, a new database named PIMBase 
is developed which integrates these well-known lists and unifies their rating scales. 
The analysis of the pharmacovigilance data reveals the benefits of combining the 
lists. PIMBase is meant to be a web-based system and starting point for the data-
driven assessment of polypharmacy to identify inappropriate medication and to 
improve the quality of prescribing. PIMBase is available at https://pimbase.kalis-
amts.de. 
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1. Introduction 
In aging populations, multimorbidity is increasing with a corresponding increase in 
polypharmacy, which in turn is the prime risk factor for inappropriate prescribing. The 
evidence is well-known by several studies that the use of certain groups of medications 
in elderly and vulnerable patients is associated with falls [1] and an increase in mortality 
[2]. Furthermore, inappropriate medications can impair cognitive properties [3], reduce 
the quality of life and cause additional costs for the healthcare system [4]. 
The major challenges in gerontopharmacology are both over-treatment and under-
treatment associated with polypharmacy. In recent years, lists, criteria and classification 
systems for assessing “potentially inappropriate medication” (PIM) for geriatric patients 
were developed and published. Besides these PIM lists of medication with a negative 
risk-benefit balance (i.e. PRISCUS [5], AUSTRIAN PIM [6]), lists with a positive 
balance (i.e. FORTA [7], EU(7)-PIM [8]) are also becoming the focus of interest. 
However, those PIM lists are spread across scientific journals and difficult to access for 
patients or health professionals in the context of treatment. The integration of the various 
lists into a uniform database and subsequent merging as well as an implementation of a 
unique rating scale are essential for the qualitative improvement of the drug therapy in 
elderly and offer opportunities for practical application to identify and reduce 
inappropriate prescribing. 
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2. Methods 
The four mentioned PIM lists are published online in different file formats and structures. 
Thus, all source structures have to be analyzed and transformed into a common schema 
in order to build up a uniform database of PIMs. Especially the machine processing 
unfriendly PDF format poses a difficult issue. Additionally, both English and German 
languages need to be supported. Whereas the FORTA list is available in both languages, 
the PRISCUS list is provided in German only. The AUSTRIAN PIM and EU(7)-PIM 
lists are only available in English. 
All lists provide the drug name, the expert consensus and selected comments or 
reasons for each PIM entry. In addition, possible therapy or drug alternatives and dose 
adjustments are listed in varying detail. Only the EU(7)-PIM list annotates each entry 
with the respective Anatomical Therapeutic Chemical (ATC) code. The FORTA list 
groups the entries by indications and the PRISCUS list provides possible contra-
indications where applicable. 
2.1. Development of the Database “PIMBase” 
First, all sources are converted into machine-readable CSV files because all PIM lists 
can be represented as tables. A simple python script parses the docx file of EU(7)-PIM 
list and saves only the relevant table as a CSV file. The other lists as PDF files were 
transferred manually. The ATC classification system is used to annotate all drug names 
with their respective ATC codes to further unify the different PIM entries for all lists. 
Additionally, the indications of the FORTA list are annotated with the International 
Classification of Diseases version 10 (ICD-10) where applicable. The transfer and 
annotation were validated by several additional people in order to ensure the consistency 
of the information extracted. 
Finally, a python script parses the four generated lists and outputs the uniform 
MySQL database. Common fields like the drug name and ratings are combined into 
uniform fields. Additional information such as source references in the EU(7)-PIM list 
or the drug class in the PRISCUS list is stored in a generic data structure of key-value-
pairs where needed.  
All PIM entries were rated by expert consensus panels of different research projects. 
A uniform rating scale was created and all PIM scores transformed into this scale in order 
to compare all scores efficiently. All lists except the FORTA scale use a 5 points Likert 
scale for rating. The FORTA list uses four categories for the PIM scores. The missing 
fifth category in comparison to the other lists is the undecided option. This option is 
introduced in order to map the FORTA list into the 5 points Likert scale. Since the order 
of score severities in the FORTA list is descending compared to the ascending severity 
in the other lists, a simple reversal of the scores results in a uniform rating scale (Table 
1). 
In future, new or updated PIM lists will be integrated semi-automatically, depending 
on the form of publication. 
 
 
 
 
 
M. Friedrichs et al. / Data-Driven Assessment of Potentially Inappropriate Medication126
Table 1. The uniform 5 points Likert scale for rating potentially inappropriate medication in PIMBase. 
1 2 3 4 5 
Drug is certainly 
potentially 
inadequate for 
older patients 
Drug is 
potentially 
inadequate for 
elderly patients 
Undecided 
Drug is not 
potentially 
inadequate for 
older patients 
Drug is certainly 
not potentially 
inadequate for 
older patients 
2.2. Implementation of the Web-based Information System 
In order to provide the contents of the PIMBase database in an easy and informative 
manner to patients and health professionals, a web-based information system was 
implemented (https://pimbase.kalis-amts.de). The main component is the search tool 
making it possible to check specific drugs by their name or ATC code for occurrence in 
the PIM lists. The integrated information outlined above is shown in a user-friendly detail 
screen and cross-linked to third-party websites (e.g. DrugBank) with further information. 
Filter parameters allow the selection of all or a subset of PIM lists to be used and the 
results can be sorted by several criteria. Finally, the results can be printed in a complete 
overview with all detail information. This print, for example, empowers patients to 
discuss the results and treatment with their general practitioners. The website uses a 
REST-API to access the database. This standalone API provides endpoints and an access 
control management for future developments and interoperability with other systems. 
3. Results 
A total of 758 different PIM entries were integrated into the PIMBase database. To 
evaluate the advantage of integrating multiple lists instead of using just a single one, the 
overlap of ATC codes present in the lists is calculated (Figure 1). 
 
 
Figure 1. Overlap of different ATC codes covered by the PIM lists. 
 
All lists only overlap in a small fraction of 16 entries. Pairs and triplets of lists show that 
an overlap is found in all combinations. However, most PIM entries can only be found 
in a single list, especially EU(7)-PIM and FORTA. This is of course biased by the size 
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and specificity of the lists. Therefore, using only a subset of the four integrated lists 
results in a loss of decision-critical information content. Because the lists differ in their 
focus on different criteria, the combination of information in the PIMBase system allows 
patients and general practitioners to evaluate different perspectives on the drugs in the 
context of treatment and improves decision-making. 
 
Evaluation of PIMBase 
The systematic analysis of the drug-related problems, i.e. adverse drug reactions (ADRs), 
is also an important aspect when evaluating the benefits of PIM lists. Therefore, cases of 
ADRs are analyzed to show the association of polypharmacy and ADRs and the benefits 
of using the lists integrated in PIMBase. 
The data is obtained from the pharmacovigilance databases of the United States 
(FAERS) [10] and Canada (CVARD) [11]. The databases contain 996,404 cases of 
patients aged 65 and older with suspected ADRs in the target population. 
The analysis of the sample population identifies a high number of cases with patients 
taking drugs referenced in PIMBase (Table 2). 47.1% of the patient cases in the 
population take at least one drug that is categorized as certainly or potentially inadequate 
for the elderly (category 1 or 2), 32.7 % take two or more inadequate drugs. 
 
Table 2. Number of patients taking at least one drug referenced in PIMBase (N (% all cases in population) per 
category). 
1 2 3 4 5 Total PIMBase lists 
Drug is certainly 
potentially 
inadequate for 
older patients 
Drug is 
potentially 
inadequate for 
elderly patients 
Undecided Drug is not 
potentially 
inadequate for 
older patients 
Drug is certainly 
not potentially 
inadequate for 
older patients 
    
232,963 
(23.4%) 
449,861 
(45.1%) 
20,496 
(2.1%) 
263,256 
(26.4%) 
312,345 
(31.3%) 
604,961 
(60.7%) 
All 
41,253 
(4.1%) 
195,107 
(19.6%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
217,439 
(21.8%) 
AUSTRIAN 
47,005 
(4.7%) 
345,035 
(34.6%) 
17,604 
(1.8%) 
0 
(0%) 
0 
(0%) 
360,418 
(36.2%) 
EU(7)-PIM 
216,347 
(21.7%) 
269,256 
(27%) 
0 
(0%) 
263,256 
(26.4%) 
312,345 
(31.3%) 
548,129 
(55.0 %) 
FORTA 
5,053 
(0.5%) 
125,152 
(12.6%) 
2,989 
(0.3%) 
0 
(0%) 
0 
(0%) 
130,941 
(13.1%) 
PRISCUS 
 
The overlap between the ADRs of the PIM lists demonstrates once again the benefit of 
combining the different lists. The FORTA list seems to be the most comprehensive list 
in this case. The FORTA list gives a more detailed classification which also takes into 
account the indication of the drug prescribed. As the EU(7)-PIM list is developed on the 
PRISCUS list,  the majority of identified cases overlap in both lists. 
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4. Discussion 
Pharmacoepidemiologic research has shown that structured interventions like the use of 
PIM lists help to identify PIMs in elderly patients [9]. The implication for research and 
daily practice should be the evaluation of interventions like decision support systems that 
incorporate knowledge sources as PIMBase to improve the assessment of polypharmacy 
and avoid inappropriate drug usage in multimorbid patients. 
5. Conclusion 
Based on the standalone PIMBase-API, the database is planned to be integrated as a 
decision support module in the KALIS system [12] for patient-specific risk assessment 
of drugs. In future, further third-party integrations of PIMBase into healthcare systems 
are possible and desirable. 
6. Availability and Requirements 
PIMBase is available at https://pimbase.kalis-amts.de via a common web-browser. 
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